Roscher, Mareike <br/><br/>
Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.  [electronic resource] 

 -  Oncotarget  Feb 2013 
 - 218-30 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.817  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alpha Particles--therapeutic use<br/>Antigens, CD20--immunology<br/>Apoptosis--radiation effects<br/>Bismuth--pharmacology<br/>Caspases--metabolism<br/>Cell Cycle--radiation effects<br/>Down-Regulation<br/>Drug Resistance, Neoplasm<br/>HL-60 Cells<br/>Humans<br/>Immunotoxins--immunology<br/>Lymphoma, Non-Hodgkin--genetics<br/>Radiation Tolerance<br/>Radioimmunotherapy--methods<br/>Radioisotopes--pharmacology<br/>Signal Transduction